Recombinant SARS-CoV-2 Beta/Omicron (BA.1/BQ.1.1/XBB.1) S-trimer protein vaccine (SinoCelltech)

重组新冠病毒 Beta/Omicron (BA.1/BQ.1.1/XBB.1)变异株 S 三聚体蛋白疫苗

Report date: 2025/06/12 17:08:45

Base Information

Drug NameRecombinant SARS-CoV-2 Beta/Omicron (BA.1/BQ.1.1/XBB.1) S-trimer protein vaccine (SinoCelltech)

Drug Alias NameCOVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer VaccineSCTV01E-2

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Vaccine type > Multivalent vaccine +[4]

Mechanisms of ActionCoronavirus spike glycoprotein modulators

TargetsCoronavirus spike glycoprotein

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesSinoCelltech Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSinocelltech Group Ltd

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A